Kestra Medical holders elect 3 directors, OK auditor

KMTS shareholders elected three Class II directors and ratified PricewaterhouseCoopers as auditor at the 2026 annual meeting, with 94.53% of eligible shares represented.

Rhea-AI Filing Summary

KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) reported the results of its 2026 annual general meeting of shareholders held on September 9, 2026. A total of 55,399,491 common shares were voted in person or by proxy, representing 94.53% of the 58,603,121 shares outstanding and entitled to vote as of July 17, 2026.

Shareholders elected Class II directors Raymond W. Cohen, Kevin Reilly, and Traci S. Umberger to serve until the 2029 annual meeting and until their successors are duly elected and qualified. Shareholders also ratified PricewaterhouseCoopers as the independent registered public accounting firm for the fiscal year ending April 30, 2027.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares voted: 55,399,491 shares Shares outstanding: 58,603,121 shares Turnout: 94.53% +4 more

7 metrics

Shares voted 55,399,491 shares Common shares voted at the 2026 annual meeting

Shares outstanding 58,603,121 shares Common shares outstanding and entitled to vote as of July 17, 2026

Turnout 94.53% Percentage of outstanding shares represented at the 2026 annual meeting

Votes for Raymond W. Cohen 37,334,685 votes Election as Class II director

Votes for Kevin Reilly 38,900,190 votes Election as Class II director

Votes for Traci S. Umberger 38,866,030 votes Election as Class II director

Votes for auditor ratification 55,356,225 votes Ratification of PricewaterhouseCoopers for fiscal year ending April 30, 2027

Key Terms

broker non-vote, independent registered public accounting firm, emerging growth company

3 terms

broker non-vote financial

"with the vote totals as set forth in the table below"

A broker non-vote happens when a brokerage firm holds shares in street name for a client but does not cast a ballot on a particular shareholder item because the broker lacks discretionary authority to vote that matter. Think of it like a person who owns a ticket but the ticket-holder refuses to vote on some issues; the share counts for ownership but not for that vote, which can affect whether proposals reach the required number of votes or a quorum.

independent registered public accounting firm financial

"the Company’s independent registered public accounting firm for the fiscal year"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

emerging growth company regulatory

"Rule 12b-2 of the Securities Exchange Act of 1934"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was the shareholder turnout at KMTS’s 2026 annual meeting?

Shareholders representing 55,399,491 common shares, or 94.53% of the 58,603,121 shares outstanding and entitled to vote as of July 17, 2026, were present in person or by proxy at Kestra Medical Technologies, Ltd.’s 2026 annual general meeting.

Which directors were elected at KMTS’s 2026 annual meeting?

Shareholders elected Raymond W. Cohen, Kevin Reilly, and Traci S. Umberger as Class II directors to serve until the 2029 annual meeting of shareholders and until their successors are duly elected and qualified.

How did KMTS shareholders vote on director nominee Raymond W. Cohen?

For director nominee Raymond W. Cohen, shareholders cast 37,334,685 votes for, 10,779,640 against, and 34,843 abstentions, with 7,259,323 broker non-votes recorded.

How did KMTS shareholders vote on director nominee Kevin Reilly?

For director nominee Kevin Reilly, shareholders cast 38,900,190 votes for, 9,204,737 against, and 35,241 abstentions, with 7,259,323 broker non-votes recorded at the 2026 annual meeting.

How did KMTS shareholders vote on director nominee Traci S. Umberger?

For director nominee Traci S. Umberger, shareholders cast 38,866,030 votes for, 9,238,943 against, and 35,195 abstentions, with 7,259,323 broker non-votes recorded at the 2026 annual meeting.

Did KMTS shareholders ratify the appointment of PricewaterhouseCoopers as auditor?

Yes. Shareholders ratified PricewaterhouseCoopers as Kestra Medical Technologies, Ltd.’s independent registered public accounting firm for the fiscal year ending April 30, 2027, with 55,356,225 votes for, 8,469 against, and 34,797 abstentions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 05:16 PM Accepted by SEC EDGAR 09/10/2026 - 05:16 PM Learn about SEC filing dates

0001877184false00-000000000018771842026-09-092026-09-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 9, 2026

KESTRA MEDICAL TECHNOLOGIES, LTD.

(Exact name of Registrant as Specified in Its Charter)

Bermuda			001-42549	Not Applicable
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
3933 Lake Washington Blvd NE Suite 200
Kirkland, Washington				98033
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (425) 279-8002

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, par value $1.00 per share		KMTS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Kestra Medical Technologies, Ltd. (the “Company”) 2026 annual general meeting of shareholders (the “2026 Annual Meeting”) was held on September 9, 2026. The total number of the Company’s common shares voted in person or by proxy at the 2026 Annual Meeting was 55,399,491, representing approximately 94.53% of the 58,603,121 shares that were outstanding and entitled to vote as of July 17, 2026, the record date of the 2026 Annual Meeting. Voting results for each matter submitted to a vote at the 2026 Annual Meeting are provided below.

Proposal 1 - Election of Directors

The shareholders elected each of the three persons named below to serve as Class II directors until the Company’s 2029 annual meeting of shareholders and until their successors are duly elected and qualified, with the vote totals as set forth in the table below:

Nominee	For	Against	Abstain	Broker Non-Vote
Raymond W. Cohen	37,334,685	10,779,640	34,843	7,259,323
Kevin Reilly	38,900,190	9,204,737	35,241	7,259,323
Traci S. Umberger	38,866,030	9,238,943	35,195	7,259,323

Proposal 2 - Ratification of Independent Registered Public Accounting Firm

The shareholders ratified the appointment of PricewaterhouseCoopers as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2027, with the vote totals set forth in the table below:

For	Against	Abstain
55,356,225	8,469	34,797

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		Kestra Medical Technologies, Ltd.
Date: September 10, 2026		By:	/s/ Brian Webster
		Name:	Brian Webster
		Title:	President and Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 33.5 KB